Tag Archives: Amgen

Biogen v. Serano – When is a Recombinant Polypeptide Novel?

Posted on May 27, 2021 by Warren Woessner

When I posted about this Fed. Cir. decision (Biogen MA v. EMD Serano, Appeal no. 2019-1133 (Fed. Cir., Sept. 28, 2020) on October 12, 2020, I viewed it as a straightforward application of the maxim that an otherwise non-novel product … Continue reading →

Posted in Anticipation | Tagged , , , | Leave a comment

Biogen v. EMD Serono – “A Nest of Limitations”

Posted on October 12, 2020 by Warren Woessner

By now, other commentators have posted on this Fed. Cir. decision (Appeal no. 2019 -1133, Sept. 28, 2020)—and found it to be a routine reversal of a district court’s relying on “source limitations” to find claims to a recombinant IFN-B … Continue reading →

Posted in Anticipation | Tagged , | Leave a comment

Novartis Wins Landmark Biosimilar Approval

Posted on March 9, 2015 by Warren Woessner

Novartis Navigates The FDA-ACA Maze – Gets Approval For Generic Neuprogen. Amgen will soon find itself in a price war with Sandoz – a Novartis company – as it tries to maintain its share of the market for Neuprogen (filgraslim). … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

Patents4Life is Six Years Old this Month. Happy Birthday to Us!

Posted on March 3, 2015 by Warren Woessner

Six years ago, In re Kubin caused a flurry of concern among biotech practitioners, and a short article on this decision was the first post on Patents4Life. That was a pretty big “story” at the time but we all had … Continue reading →

Posted in Miscellaneous | Tagged , , , , , , , , , | 4 Comments